Viewpoint Capital Management LLC Purchases 4,500 Shares of Sana Biotechnology, Inc. $SANA

Viewpoint Capital Management LLC increased its position in Sana Biotechnology, Inc. (NASDAQ:SANA) by 19.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 28,045 shares of the company’s stock after acquiring an additional 4,500 shares during the quarter. Viewpoint Capital Management LLC’s holdings in Sana Biotechnology were worth $77,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of SANA. Charles Schwab Investment Management Inc. grew its position in shares of Sana Biotechnology by 0.9% in the first quarter. Charles Schwab Investment Management Inc. now owns 1,066,304 shares of the company’s stock valued at $1,791,000 after purchasing an additional 9,792 shares during the last quarter. Woodline Partners LP boosted its stake in Sana Biotechnology by 13.1% during the 1st quarter. Woodline Partners LP now owns 780,656 shares of the company’s stock valued at $1,312,000 after purchasing an additional 90,515 shares during the period. Deutsche Bank AG grew its holdings in Sana Biotechnology by 87.9% in the 1st quarter. Deutsche Bank AG now owns 666,392 shares of the company’s stock valued at $1,120,000 after buying an additional 311,692 shares during the last quarter. AQR Capital Management LLC grew its holdings in Sana Biotechnology by 49.8% in the 1st quarter. AQR Capital Management LLC now owns 573,146 shares of the company’s stock valued at $963,000 after buying an additional 190,483 shares during the last quarter. Finally, Clearline Capital LP acquired a new stake in Sana Biotechnology in the 1st quarter valued at approximately $690,000. 88.23% of the stock is currently owned by institutional investors.

Sana Biotechnology Trading Up 5.1%

NASDAQ SANA opened at $4.16 on Tuesday. Sana Biotechnology, Inc. has a 1-year low of $1.26 and a 1-year high of $7.30. The company has a market capitalization of $989.29 million, a price-to-earnings ratio of -3.92 and a beta of 1.91. The stock’s 50 day moving average is $3.42 and its two-hundred day moving average is $2.81.

Sana Biotechnology (NASDAQ:SANA) last issued its earnings results on Monday, August 11th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.04. On average, analysts predict that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current year.

Analyst Upgrades and Downgrades

SANA has been the subject of several research reports. Wedbush initiated coverage on Sana Biotechnology in a research report on Wednesday, September 24th. They issued an “outperform” rating and a $5.00 price objective for the company. JMP Securities reissued a “market outperform” rating and issued a $5.00 price target on shares of Sana Biotechnology in a report on Tuesday, June 24th. Morgan Stanley began coverage on shares of Sana Biotechnology in a report on Thursday, July 3rd. They set an “overweight” rating and a $12.00 price objective on the stock. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Sana Biotechnology in a research note on Saturday, September 27th. Seven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Sana Biotechnology has a consensus rating of “Moderate Buy” and a consensus price target of $7.50.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.